English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNeutralizing antibodies recognize the coronavirus and block it.
Tag: Antibody test
Response to COVID-19 Vaccines Varies Widely in Blood Cancer Patients
Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines—in some cases, no detectable response—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published in Cancer Cell in June.
New partnership to develop a new ultra-fast test for COVID-19 antibodies
The NanoSpot.AI test is estimated to be significantly less expensive to manufacture than other SARS-CoV-2 antibody tests and has the potential to be more affordable than currently available tests, making it possible to extend the test to every corner of the world. Clinical studies validating NanoSpot.AI are currently underway.
No more needles?
Blood draws are no fun.They hurt. Veins can burst, or even roll — like they’re trying to avoid the needle, too.Oftentimes, doctors use blood samples to check for biomarkers of disease: antibodies that signal a viral or bacterial infection, such as SARS-CoV-2, the virus responsible for COVID-19, or cytokines indicative of inflammation seen in conditions such as rheumatoid arthritis and sepsis.
New Saliva-Based Antibody Test for SARS-CoV-2 Highly Accurate in Initial Study
A new saliva-based test developed by a team at Johns Hopkins Bloomberg School of Public Health has been found to accurately detect the presence of antibodies to SARS-CoV-2, the virus that causes COVID-19.
Mount Sinai Selected to Serve as Capacity Building Center and Center of Excellence as Part of the National Cancer Institute’s New Serological Sciences Network
Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute (NCI) as part of the NCI’s new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19. Mount Sinai was selected as one of only four Capacity Building Centers and one of eight Centers of Excellence as part of this new network.
Coronavirus antibodies fall dramatically in first 3 months after mild cases of COVID-19
A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 73 days. If sustained at that rate, the antibodies would disappear within about a year.
UNC-Chapel Hill Researchers Create New Type of COVID-19 Antibody Test
UNC Chapel Hill scientists created a test that pinpoints human antibodies specific to a unique part of the SARS-CoV-2 spike protein. The test can help document COVID-19 infections, identify asymptomatic virus infection, and measure the level of immunity in individuals.
Researchers work to quantify the human immune response to COVID-19
Notre Dame’s Merlin Bruening and a team of scientists have begun research to develop point-of-care antibody tests that would help public health officials to better understand how an individual’s immunity to COVID-19 lasts over time.
COVID-19: What You Need to Know About Antibody Testing
As the number of COVID-19 cases in the U.S. surpasses 800,000, many Americans want to know if recovered patients have immunity to the novel coronavirus. The answer could come from an antibody test. While these tests are commonly used to tell if someone is immune to diseases such as measles or chickenpox, they’re not yet widely available for COVID-19. But it’s not clear what the results would mean.
Penn Medicine Launches COVID-19 Convalescent Plasma Study
Convalescent plasma therapy for COVID-19 patients — an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection — is the focus of a new two-part research initiative at Penn Medicine. Researchers will first collect plasma from people who have recovered from their infection under a donor research protocol. The second part involves conducting clinical trials to test the safety and efficacy of giving that plasma to moderately and severely ill hospitalized patients.